Related by context. All words. (Click for frequent words.) 78 Gastrointestinal Cancers Symposium 77 Genitourinary Cancers Symposium 70 ASCO Annual Meeting 69 Digestive Disease Week DDW 69 Prostate Cancer Symposium 69 Hematology ASH Annual Meeting 69 AACR #nd Annual Meeting 69 Digestive Diseases Week 69 AACR NCI EORTC 69 nd Annual Meeting 68 Breast Cancer Symposium 68 AHA Scientific Sessions 68 AACR #st Annual Meeting 68 AACR San Antonio 68 ASH Annual Meeting 67 Pediatric Academic Societies PAS 67 Endocrine Society #nd 66 Pediatric Academic Societies 66 CTRC AACR San Antonio 66 ASCO GU 66 Digestive Disease Week 66 Endocrine Society Annual Meeting 66 ICAAC IDSA 66 #th Annual Interscience 66 ADA Scientific Sessions 65 ASCO GI 65 Clinical Oncology Annual Meeting 64 Hematology Annual Meeting 64 Society CTOS 64 AAAAI Annual Meeting 64 Annual Scientific Sessions 64 Clinical Oncology ASCO Annual 64 ECTRIMS 63 Pediatric Academic Society 63 Breast Cancer Symposium SABCS 63 Cancers Symposium 63 Rheumatology Annual 63 CROI 63 BIOCOM Investor Conference 63 AUA Annual Meeting 63 SABCS 62 Connective Tissue Oncology 62 Nephrology Renal Week 62 ASCO Gastrointestinal Cancers Symposium 62 Hematology ASH 62 Opportunistic Infections CROI 61 Canaccord Adams Hepatitis C 61 Gastroenterology ACG Annual 61 Transcatheter Cardiovascular Therapeutics TCT 61 Rheumatology ACR Annual 61 ICAAC 61 #nd Annual Meeting 61 Neurology AAN 61 Hematology Meeting 61 ASCO Breast Cancer 61 Endocrine Society #st 61 Endocrine Society ENDO 60 ASGT 60 st Annual Meeting 60 AASLD 60 Therapeutics TCT scientific 60 #rd Annual CTRC 60 SAEM Annual Meeting 60 International Myeloma Workshop 60 Transcatheter Cardiovascular Therapeutics 60 Vascular Annual Meeting 59 PRNewswire FirstCall Amylin Pharmaceuticals 59 #nd EORTC NCI 59 Inc. Nasdaq AMLN 59 Related Disorders ICAD 59 #st Annual Meeting 59 Clinical Oncologists 59 ISPOR 59 BIO InvestorForum 59 Symposium SABCS 59 Neurology Annual Meeting 59 AAN Annual Meeting 58 ORAL Sync 58 Cardiology Scientific Sessions 58 Inc. Nasdaq OPTR 58 PROSTVAC TM 58 Alzheimer Disease ICAD 58 Cancer iSBTc 58 Heart Failure Society 58 AACR IASLC Joint 58 annual Transcatheter Cardiovascular 58 Therapeutics TCT 58 Arteriosclerosis Thrombosis 58 Biological Therapy 58 Annual Transcatheter Cardiovascular 58 American Psychosomatic Society 58 Chicago Multidisciplinary Symposium 58 Immunology Annual Meeting 58 EORTC NCI 58 GASTRO 58 Vascular Biology ATVB 58 ECCMID 58 AACR Frontiers 57 EORTC NCI AACR 57 Biotech Showcase 57 Cell Biology ASCB 57 Scientific Sessions 57 USpella 57 Liver Diseases AASLD 57 #th Interscience Conference 57 Retrovirus Conference 57 League Against Rheumatism 57 Phase Ib study 57 Phase III ALLEGRO 57 Chemotherapy ICAAC 57 teriflunomide 57 European CanCer Organisation ECCO 57 AACR Annual Meeting 56 alvespimycin 56 midstage clinical 56 UEGW 56 American Urological Association 56 phase 2a 56 BRIM3 56 AAO HNSF Annual Meeting 56 Poster Discussion 56 Scientific Session 56 AAAS Annual Meeting 56 ARVO Annual Meeting 56 Keystone Symposia 56 ASTRO Annual Meeting 56 ongoing Phase 1b 56 NASDAQ CYTK announced 56 Hematology ASH Meeting 56 EASD 56 & Immunology AAAAI 56 Molecular Targets 56 CLSA AsiaUSA Forum 56 ARVO 56 NASDAQ CXSP announced 56 VEITHsymposium 55 EORTC NCI AACR Symposium 55 Lysosomal Disease Network 55 MEND CABG 55 AVERROES 55 evaluating mipomersen 55 Phase Ib clinical 55 phase IIb 55 EuroPCR 55 Phase 1b trial 55 HORIZONS AMI trial 55 PROTECT II 55 Clinical Oncology Gastrointestinal Cancers 55 evaluating tivozanib 55 ACR ARHP 55 Neurological Surgeons Annual Meeting 55 San Antonio Breast Cancer 55 DDW ® 55 America HFSA 55 ToGA 55 Atrial Fibrillation Symposium 55 Gastroenterology ACG 55 Rheumatology Annual Meeting 55 ASCO 55 th Interscience Conference 55 Radiation Oncology ASTRO 55 Maternal Fetal Medicine SMFM 55 AABB Annual Meeting 55 Phase 2a clinical 55 Clinical Trials Update 55 Experimental Biology EB 55 TG MV 55 phase IIb study 55 CRLX# 55 Midyear Clinical Meeting 55 EGS# 55 AASLD Meeting 55 Late Breaker 55 ENDEAVOR III 55 AACR Meeting 55 Canaccord Genuity Healthy Living 55 Clinical Virology Symposium 55 Clinical Oncology ASCO 55 Canaccord Genuity Musculoskeletal 55 Breaking Clinical Trials 55 ACR ARHP Annual 54 AACR NCI EORTC Molecular 54 Spine Arthroplasty Society 54 YONDELIS 54 phase IIa clinical 54 CLEO QELS 54 pertuzumab 54 EFNS 54 ASBMR 54 LymphoStat B 54 seliciclib CYC# 54 KRN# 54 NASDAQ INHX 54 Oncology ASTRO 54 PRNewswire FirstCall Nektar Therapeutics 54 Cardiovascular Disease Epidemiology 54 non nucleoside inhibitor 54 oral rivaroxaban 54 entitled Synergistic 54 Therapeutic Radiology 54 registrational Phase 54 elotuzumab 54 oral FTY# 54 Cystic Fibrosis Conference NACFC 54 chromium supplementation 54 Phacilitate Vaccine Forum 54 placebo controlled clinical 54 Malignant Lymphoma 54 phase IIa 54 PRNewswire FirstCall Ardea Biosciences 54 Phase III ADT 54 Investor Luncheon 54 AACR EORTC NCI 54 EULAR Annual 54 Liver Meeting 54 Endovascular Therapy ISET 54 Pharmaceutical Scientists AAPS 54 ExTRACT TIMI 54 Zarnestra 54 EXPAREL ™ 54 Fifth Decennial International 54 metastatic castration resistant 54 rALLy trial 54 FDA Oncologic Drugs 54 ERA EDTA 54 NASDAQ SLXP today 53 ABCSG 53 ECCO ESMO 53 AAAS Fellows Forum 53 phase IIb trial 53 Drugs Affecting Lipid 53 Antimicrobial Agents 53 Hedgehog Pathway Inhibitor 53 Tanespimycin 53 Nasdaq SNSS 53 CAMMS# 53 EOquin TM 53 ® DDW 53 MERLIN TIMI 53 PRNewswire FirstCall Tercica 53 rivaroxaban Xarelto 53 Scientific Meeting 53 Nasdaq DNDN 53 multicenter Phase II 53 American Thoracic Society 53 Inc. Nasdaq BIOD 53 ZYBRESTAT fosbretabulin 53 Opportunistic Infections 53 RECORD1 53 Medical Oncology ESMO 53 multicenter Phase 53 Randomized Phase 53 TACI Ig 53 #th Annual Retrovirus 53 Phase #/#a trial 53 viral kinetic 53 Molecular Medicine Tri 53 SUCCEED trial 53 randomized Phase III 53 PROVENGE sipuleucel T 53 Advanced Neuroendocrine Tumors 53 CTAP# Capsules 53 Hypertension ASH 53 Global Healthcare Unplugged 53 CIMZIA TM certolizumab pegol 53 ECNP 53 phase IIb clinical 53 Intervention Effectiveness 53 ixabepilone 53 SCCHN 53 MERIT ES 53 PRNewswire FirstCall Genaera 53 American Roentgen Ray 53 AIR2 Trial 53 HORIZONS AMI 53 TASKi2 53 ASCO Prostate Cancer 53 Traficet EN 53 Ambrisentan 53 ENDEAVOR IV 53 Selective Cardiac Myosin 53 PROactive Study 53 Clinical Oncology ASCO Gastrointestinal 53 Amrubicin 53 NEUVENGE 53 Pirfenidone 53 INCB# [001] 53 Nasdaq PCYC 53 TORISEL TM 53 novel VDA molecule 53 Dacogen injection 53 INSPIRE Trial Phase III 53 radezolid 52 Nasdaq ENZN 52 iSBTc 52 evaluating REVLIMID 52 PROTECT AF 52 Ophthalmology ARVO 52 Daclizumab 52 Nasdaq CYCC Nasdaq CYCCP 52 Inc. NASDAQ HEPH 52 R roscovitine 52 Canaccord Adams Musculoskeletal 52 brivaracetam 52 Nasdaq MBRX announced 52 Printable slides 52 Liver EASL 52 LibiGel testosterone gel 52 oral ridaforolimus 52 Neck Surgery Foundation 52 anti arrhythmic drug 52 liposome injection 52 ganetespib 52 Phase III AFFIRM 52 Annual ICAAC 52 Gastrointestinal Cancer 52 Group RTOG 52 dose escalation clinical 52 randomized discontinuation trial 52 AACR symposium 52 HCV SPRINT 52 sipuleucel T 52 ASCO abstract 52 preclinical efficacy 52 Nexavar sorafenib 52 Ocrelizumab 52 Clinical Trial Results 52 Poster Presentation 52 Clinical Chemistry AACC 52 Nordic ACTI 52 BRIM2 52 Mineral Research ASBMR 52 randomized controlled Phase 52 assessing T DM1 52 International Neuropsychological Society 52 Gene Therapy ASGT 52 Molecular Origins 52 NCCTG N# 52 preclinical pharmacokinetic 52 sorafenib tablets 52 AA Amyloidosis 52 SPIRIT IV 52 AVADO 52 ThinkEquity Partners Growth 52 Elagolix 52 Oral Fingolimod 52 Nasdaq VPHM 52 riociguat 52 Gynecologic Cancer Society 52 MGd 52 Deforolimus 52 CTI Nasdaq 52 RGB # 52 Vaccine Immunology 52 ACC.# 52 ACUITY trial 52 Epilepsy Society 52 Phase Ib II 52 APPRAISE 52 neratinib 52 Urocortin 2 52 XL# SAR# 52 Research IADR 52 Clinical Endocrinologists AACE 52 Phase #b/#a clinical 52 proteasome inhibitor 52 International Microwave Symposium 52 Inc. Nasdaq SGEN 52 recurrent glioma 52 Belimumab 52 Phase III VISTA 52 CoreNet Global Summit 51 huC# DM4 51 PEG SN# 51 AAPS Annual Meeting 51 Neoplasia 51 Infectious Diseases ECCMID 51 Phase IIB 51 TTF Therapy 51 developer Antisoma plc 51 Combination REOLYSIN R 51 Natalizumab 51 BiTE R 51 phase IIIb 51 Oligonucleotide Therapeutics Society 51 SYNTAX trial 51 Plicera 51 BOLDER II 51 CLARITY TIMI 51 SYMMETRY trial 51 NO# [002] 51 Pyridorin 51 Gynecologic Investigation 51 pharmacokinetic PK 51 ESTRO 51 Inc. Nasdaq ANDS 51 Clinical Antipsychotic Trials 51 Tesmilifene 51 GTCbio 51 Reverset 51 Phase 2a trial 51 VoiceCon Fall 51 OneMedPlace Finance Forum 51 FOLOTYN ® 51 relapsed multiple myeloma 51 CEQ# 51 Prostate AdenoCarcinoma Treatment 51 Dr. Agarwala 51 NAASO 51 HCV NS5B polymerase 51 recurrent glioblastoma multiforme 51 bazedoxifene conjugated estrogens 51 EASL 51 Zenvia Phase III 51 ORMD 51 phase Ib 51 PreCISe 51 axitinib 51 Institutional Investor Forum 51 Val HeFT 51 HCV polymerase inhibitors 51 ThermoDox ® clinical 51 fosbretabulin 51 Interventional Radiology SIR 51 CALGB # [002] 51 BCIRG 51 Hematology 51 Lung Transplantation 51 Human Genetics ASHG 51 IL# PE#QQR 51 Poster Session 51 Thomas Weisel Partners Tech# 51 NAREIT REITWeek 51 SAWC WHS 51 LD MICRO Conference 51 HCV RESPOND 2 51 pediatric acute lymphoblastic 51 Onrigin 51 Long Awaited Reality 51 Faslodex 51 Digital Mammographic Imaging 51 cetuximab Erbitux 51 PERSEUS clinical program 51 Phase III ThermoDox 51 International Papillomavirus 51 Solid Tumors 51 multicenter clinical 51 Cardiovascular Therapeutics 51 EURIDIS 51 galiximab 51 ICAD 51 ATACAND 51 Phase III psoriasis 51 BR.# 51 PRNewswire FirstCall Oncothyreon 51 Glucosamine Chondroitin Arthritis 51 II Clinical Trial 51 tanespimycin 51 EULAR 51 prostate cancer mCRPC 51 PANVAC VF 51 GVAX ® 51 EVEREST II 51 OXi# 51 Interventions SCAI 51 substudy 51 PROactive study 51 journal Antimicrobial Agents 51 Nasdaq OPTR 51 enzastaurin 51 Natixis Bleichroeder Hidden Gems 51 Zemplar Capsules 51 Folfox 51 NSTI Nanotech 51 randomized Phase IIb 51 Genta Incorporated OTCBB GETA 51 OTCBB AOLS announced 51 Room #AB [002] 51 pharmacokinetic PK study 51 MATCHED 51 PEARL HF 51 CombAT 51 midstage trials 51 Xelox 51 trial evaluating PRX# 51 ABRF 51 PERSEUS 51 ONTARGET 51 farletuzumab 51 Neuropsychopharmacology 51 blinatumomab 51 Inc. Nasdaq AVRX 51 Phase 2a 51 CARE HF 51 Denufosol 51 Canaccord Genuity Growth 51 SCAI Annual 51 Respiratory Viral Infections 51 ENDO 51 CTRC AACR 51 Clinical Oncology 51 Cardiology ACC 51 Ovarian PLCO Cancer 50 JPMorgan SMid Cap 50 CUSTOM III 50 Rheumatology ACR 50 resistant hormone refractory 50 Liver Disease AASLD 50 Windhover Therapeutic Area 50 Cardiostim 50 LymphoStat B TM 50 metastatic hormone refractory 50 Selective Cardiac Myosin Activator 50 Addex Pharmaceuticals SIX ADXN 50 randomized multicenter trial 50 AGBT 50 Storer Auditorium 50 PSN# [002] 50 Needham Biotechnology 50 Neuropathic Pain 50 recurrent GBM 50 subanalysis 50 Screening Trial 50 Anti Infective Drugs 50 Teriflunomide 50 fidaxomicin Phase 3 50 oral Xeloda 50 Neuro Oncology SNO 50 Delcath Phase III 50 Personalized Immunotherapy 50 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 50 HQK 50 delafloxacin 50 BIO VentureForum East 50 CLL8 50 romidepsin 50 Talabostat 50 perifosine KRX 50 ALA Midwinter Meeting 50 telcagepant 50 INVESTIndiana Equity Conference 50 CYT# potent vascular disrupting 50 vidofludimus 50 ELACYT 50 Sipuleucel T 50 journal Hepatology 50 Anesthesiologists Annual Meeting 50 Lehman Brothers T4 50 Lung Cancer IASLC 50 Doxil ® 50 orally inhaled migraine 50 Phase #/#a 50 atacicept 50 diagnosed glioblastoma 50 compound AEZS 50 ECASS 50 NSABP C 50 ESMO 50 number NCT# ClinicalTrials.gov 50 OTO EXPO 50 Temsirolimus 50 Aggressive Reduction 50 PEGylated interferon beta 1a 50 Breast Surgeons 50 LSE ASM 50 RIO Lipids 50 ISPE Annual Meeting 50 Overactive Bladder OAB 50 vismodegib 50 depsipeptide 50 Oral Presentation 50 Therapeutic Radiation 50 LD Micro 50 SPIE Photonics West 50 lintuzumab 50 novel trazodone formulation 50 Aflibercept 50 EUROGIN 50 REITWeek 50 OncoVex 50 Safinamide 50 CALGB 50 Immunology ACAAI 50 LUX Lung 50 prospective multicentre 50 Phase 1b clinical trials 50 verteporfin 50 Cardiology ESC Congress 50 JMP Securities Healthcare 50 Optical Fiber Communications 50 Menopause Society NAMS 50 trastuzumab DM1 T DM1 50 eltrombopag 50 HuMax EGFr 50 CIMZIA ™ 50 Aryplase 50 recurrent malignant glioma 50 Omacetaxine 50 randomized Phase 2b 50 Vandetanib 50 trastuzumab DM1 50 NASDAQ PCYC 50 forodesine 50 Metastatic Melanoma 50 Inc. Nasdaq SGMO 50 Cachexia 50 Luxe Sunset Bel Air 50 Phase III placebo controlled 50 Hepatology journal 50 MDV# 50 CODiE Awards Gala 50 Antibody Therapeutics 50 NASDAQ ARRY 50 MelaFind pivotal 50 MEND CABG II 50 HYVET 50 Dr. Gulfo 50 Nasdaq GENR 50 transthyretin TTR mediated amyloidosis 50 Ixempra 50 Pharmacoeconomics 50 ThinkEquity Growth 50 Romiplostim 50 Annual Interscience Conference 50 INCB# [002] 50 SA FC# 50 Plastic Surgeons ASPS Plastic 50 CHAMPION PCI 50 Idenix Pharmaceuticals 50 & OTO EXPO 50 IPAA OGIS 50 Needham Growth Conference 50 rosuvastatin Crestor 50 SCTE Cable Tec EXPO 50 PRNewswire FirstCall Bionovo 50 Promacta 50 Neurological Surgeons AANS 50 http:/www.vivus.com 50 Romidepsin 50 J.P. Morgan Healthcare 50 Diabetologia 50 amrubicin 50 Anticancer Drugs 50 Ophthalmic Drugs Advisory 50 PRNewswire FirstCall ViroPharma Incorporated 49 MYTHOS trial 49 rALLy clinical trial 49 FOLFOX6 chemotherapy regimen 49 Venereology EADV 49 Nephrology ASN Renal 49 Virulizin ® 49 Quinamed 49 REG2 49 perifosine 49 Brentuximab Vedotin SGN 49 morphometric vertebral fractures 49 iclaprim 49 HIF PHI 49 RECIST Response Evaluation Criteria 49 Anesthesiologists ASA Annual Meeting 49 PXD# 49 Endocrine Society 49 ZYBRESTAT 49 NATRECOR ® 49 RE LY 49 oral proteasome inhibitor 49 C# BioVentures Conference 49 SAR# [004] 49 refractory chronic myeloid 49 ASH Abstract # 49 Retroviruses 49 NCVH 49 www.nejm.org 49 Zybrestat 49 Bazedoxifene 49 Initiated Phase 49 including eniluracil ADH 49 tasocitinib 49 Ophthalmology ARVO Annual Meeting 49 J Clin Oncol 49 CT Colonography Trial 49 picoplatin 49 Phase Ib 49 Liver Diseases 49 multicenter trials 49 Inc. Nasdaq VRUS 49 PROSTVAC VF 49 Carfilzomib 49 Velcade bortezomib 49 DDW 49 Refractory Angina 49 maximally tolerated dose 49 SID Display Week 49 Inc. NASDAQ SGEN 49 tolerability profiles 49 Cardiovascular Renal Physiology 49 AACR 49 Stenting Trial CREST 49 Targeted Anticancer Therapies 49 Unither 49 investigational immunotherapy 49 Postgraduate Course 49 ImmunoVEX HSV2 49 Amgen NASDAQ AMGN 49 EchoCRT 49 thetreatment 49 Tesetaxel 49 HeFT 49 BioPharm America 49 Antiviral Research 49 TRO# 49 TMC# C# 49 MOZOBIL 49 metaglidasen 49 Arch Intern Med 49 Headache Society 49 Nasdaq ONXX today 49 Allovectin 7 ® 49 statistically significant efficacy 49 TXPO 49 neoadjuvant treatment 49 ZACTIMA 49 Equine Practitioners Convention 49 Femara letrozole 49 Canaccord Genuity Cardiovascular 49 Ceflatonin 49 Macula Society 49 Archexin 49 EDEMA3 trial 49 ROCKET AF 49 cediranib 49 sunitinib malate 49 ON #.Na 49 Oral Presentations 49 Aplidin R 49 KRAS status 49 R lenalidomide 49 Preclinical Study 49 Heart Assn 49 Cloretazine ® 49 Glufosfamide 49 ICR XChange Investor 49 HuMax CD4 49 Hsp# Inhibitor 49 Oncologic Drugs Advisory 49 HIMSS# Interoperability Showcase 49 Pemetrexed 49 Ophthalmology AAO 49 bevacizumab Avastin 49 Recurrent Chest Wall 49 LIGHTFAIR International 49 metastatic CRC 49 Relapsing Multiple Sclerosis 49 ZD# [001] 49 SPIRIT III 49 AAG geldanamycin analog 49 aclidinium bromide 49 Gastroenterology Week UEGW 49 GRN#L 49 Eur J Neurol 49 ENMD # 49 CLARITY study 49 Acute Myocardial Infarction 49 Diabetes EASD 49 NAREIT Investor Forum 49 Therapeutic Approaches 49 Tolvaptan 49 PROLARIS 49 GOUT 49 Pooled Analysis 49 Anesthesiologists ASA 49 abstracts summarizing 49 angiogenesis inhibitor 49 Genasense ® 49 atrasentan 49 BioContact Quebec 49 Nasdaq CLSN 49 ASM Biodefense 49 Active Biotech NASDAQ OMX 49 mg administered orally 49 satraplatin Phase 49 ENESTnd 49 Dr. Pingpank 49 VoiceCon Spring 49 PROSTVAC ® 49 Hematologic 49 Edge STudy 49 Amorcyte 49 Molecular Cancer 49 Sprycel dasatinib 49 CR# vcMMAE 49 REALITY Trial 49 PSMA ADC 49 Nasdaq GNTA 49 selective kinase inhibitor 49 AVN# Phase 49 ISSWSH 49 Phase 2b Clinical Trial 49 pharmacodynamic properties 49 velafermin 49 EGEN 49 Phase 2b trial 49 Cytokinetics Incorporated NASDAQ CYTK 49 Arimidex anastrozole 49 Nasdaq SGMO announced 48 CSCMP Annual Conference 48 clinical pharmacology studies 48 hormone refractory metastatic prostate 48 Gleevec imatinib mesylate 48 Two Investor Conferences 48 BHIVA 48 pralatrexate injection folate analogue 48 Breast Surgeons ASBS 48 Nutracon 48 APOPTONE 48 Randomized Phase III 48 Cardiovascular Anesthesiologists 48 oncolytic virus therapies 48 Randomized Phase II 48 relapsing remitting MS RRMS 48 Inc. Nasdaq BNVI 48 HIMSS Annual 48 Inc. Nasdaq CRTX 48 Retina Specialists 48 Neurology AAN Annual Meeting 48 Inc. Nasdaq IMGN 48 indolent follicular non 48 pharmacokinetic pharmacodynamic 48 SuperCommunity Bank Conference 48 multicenter randomized controlled 48 Nasdaq ALXN 48 Gynecological Cancer 48 EORTC 48 onNovember 48 Hodgkin lymphoma HL 48 Phase 2a Study 48 PARTNER Trial 48 pancreatic colon 48 Nasdaq INCY announced 48 PRNewswire FirstCall Northwest Biotherapeutics 48 Double Blind Placebo 48 deforolimus 48 Molecular Markers 48 REGiMMUNE 48 sorafenib Nexavar 48 PRNewswire FirstCall Genta Incorporated 48 Azedra 48 Uplinq 48 Acute Decompensated Heart Failure 48 Perinatal Epidemiology 48 GENASIS 48 ASN Renal Week 48 Pertuzumab 48 Gastrointestinal Oncology 48 PNP inhibitor 48 Pharmacoeconomic 48 journal Lancet Neurology 48 eniluracil 48 ATVB 48 Surgical Oncology SSO 48 Inflammatory Bowel Diseases 48 Cholesterol Levels SPARCL 48 GRNCM1 48 investigational antiplatelet 48 IPAA OGIS San Francisco 48 Solorel TM 48 ASCRS 48 dose escalation trial 48 Health ISSWSH 48 LibiGel Phase III 48 ACOMPLIA R 48 RTOG 48 ASGCT 48 Bevacizumab Avastin 48 Neurological Societies 48 Multiethnic Study 48 Urology EAU 48 BiTE antibody MT# 48 Tocosol Paclitaxel 48 DASISION 48 NACDA Convention 48 Phase 2a Trial 48 PFO migraine 48 Cambridge Healthtech Institute 48 ARRS Annual Meeting 48 Inc. Nasdaq TPTX 48 System Pharmacists ASHP 48 Interscience Conference 48 NCCN guidelines 48 Panzem R 48 Obesity Reviews 48 PRIMO CABG2 48 Photovoltaics Summit 48 Cardiology ESC 48 Hypertension ESH 48 Heart Failure Therapies 48 Gemzar ® 48 OneMedForum 48 worsening thrombocytopenia 48 relapsed refractory multiple myeloma 48 cabozantinib 48 Glatiramer acetate 48 mGluR5 negative 48 Rexahn Pharmaceuticals 48 SPIRIT FIRST 48 COU AA 48 Annual AIFA 48 th Annual Interscience 48 histone deacetylase HDAC inhibitor 48 ponatinib 48 acute STEMI 48 ISTH 48 NAREIT Investor 48 IRX 2 48 Hemispherx Biopharma 48 SIR Spheres 48 EINSTEIN DVT 48 peginesatide 48 AEG# 48 vandetanib 48 Canaccord Adams Healthy Living 48 Endocrine Practice 48 GLOBE NEWSWIRE Pressure BioSciences 48 Malignant Mesothelioma 48 HGS ETR1 48 Brachytherapy Society 48 journal Neuropsychopharmacology 48 figitumumab 48 Hormone Refractory Prostate Cancer 48 SPIRIVA HandiHaler 48 tolvaptan 48 www.aacr.org 48 Inc. Nasdaq MLNM 48 CYT# 48 Scrip Awards 48 Phase 2b RESTORE CLI 48 Chest Physicians CHEST 48 Neuropsychopharmacology ACNP 48 entinostat 48 Fuel Cell Seminar 48 trabectedin 48 ThermoDox R 48 PKC# 48 vascular disrupting agent 48 Dabigatran 48 HFSA Annual 48 ProSavin 48 essential thrombocythemia ET 48 Stem Cell Research ISSCR 48 Hana Biosciences 48 TAMPA FL eMediaWorld 48 NEVO RES 48 Hematological Malignancies 48 Inc. Nasdaq INFI 48 Oncotype DX TM 48 Pre RELAX AHF 48 Randomized Double blind 48 Refractive Surgery ASCRS 48 intravenous bisphosphonates 48 Castration Resistant Prostate Cancer 48 Lung Cancer WCLC 48 NAREIT REITWorld 48 huN# DM1 48 Trastuzumab DM1 48 Angiolix 47 metastatic HRPC 47 Antimicrobial Chemotherapy 47 Guanilib 47 paclitaxel cisplatin 47 ASMS Conference 47 plus Copegus R 47 BioNumerik 47 Vical Incorporated 47 metastatic renal cell carcinoma 47 Aggressive Drug Evaluation 47 Investment Symposium OGIS 47 Myelodysplasia 47 NSABP 47 Hyphanox 47 prospective observational 47 ROTH #nd 47 Inc. Nasdaq ATHX 47 varespladib 47 Frankfurt XMP 47 carotid artery stenting CAS 47 Gaylord Palms Hotel 47 Canvaxin 47 AP# [003] 47 AIM HIGH 47 LBH# 47 APTIVUS R 47 #-#,# [015] 47 Zoledronic acid 47 SIX ATLN 47 Breaking Clinical Trial 47 oral prodrug 47 efficacy tolerability 47 Inc. NASDAQ AGIX 47 plerixafor